HOXA4 and ovarian carcinoma: Also, higher expression of HOXA4 was associated with a shorter progression‐free survival in 71 patients with ovarian cancer undergoing adjuvant platinum‐based chemotherapy (HR 1.20, 95% CI 1.07–1.34) [39].